title: Intravitreal tanibirumab, a fully human monoclonal antibody against vascular endothelial growth factor receptor 2, partially suppresses and regresses laser-induced choroidal neovascularization in a rat model.
abstract: OBJECTIVE
  The study investigated the effect of intravitreally administered tanibirumab, a fully human monoclonal antibody against vascular endothelial growth factor receptor 2, in a rat model of laser-induced choroidal neovascularization (CNV).
  
  
  METHODS
  CNV was induced by laser photocoagulation on day 0 in the eyes of Brown Norway rats. Intravitreal injection of tanibirumab or phosphate-buffered saline (PBS) was done on day 0 (prevention arm) or day 7 (treatment arm). Seven days after injection, the eyes were enucleated and retinal pigment epithelium-choroid-sclera flat mounts were prepared. Areas of CNV were determined in the flat mounts using tetramethylrhodamine isothiocyanate Bandeiraea simplicifolia (BS) isolectin labeling and intravenously administered fluorescein isothiocyanate-dextran and quantified using an image analysis program.
  
  
  RESULTS
  In the prevention arm, the mean area of CNV measured by BS isolectin labeling was reduced by 28.2% and 53.9% in tanibirumab-treated eyes (20 and 60 μg, respectively) compared with PBS-treated control eyes on day 7 (P=0.038 and P<0.001, respectively). In the treatment arm, the mean area of CNV measured by BS isolectin labeling was reduced by 28.7% and 46.0% in tanibirumab-treated eyes (20 and 60 μg, respectively) compared with PBS-treated control eyes on day 14 (P=0.048 and P<0.001, respectively).
  
  
  CONCLUSIONS
  Intravitreally administered tanibirumab partially suppressed the formation of new CNV and partially regressed preformed laser-induced CNV in the rat model. Tanibirumab may be a feasible treatment for CNV associated with age-related macular degeneration or other causes.
authors.affiliation: 1 The Laboratory of Vascular Biology and Stem Cells, Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST) , Daejeon, Republic of Korea.
authors.forename: Jaeryung
authors.initials: J
authors.lastname: Kim
authors.forename: Tae Eun
authors.initials: TE
authors.lastname: Kim
authors.forename: Ju-A
authors.initials: JA
authors.lastname: Kim
authors.forename: Ji-Hyun
authors.initials: JH
authors.lastname: Yun
authors.forename: Seongsoo
authors.initials: S
authors.lastname: Sohn
authors.forename: Sang Ryeol
authors.initials: SR
authors.lastname: Shim
authors.forename: Sang Hoon
authors.initials: SH
authors.lastname: Lee
authors.forename: Sang Jin
authors.initials: SJ
authors.lastname: Kim
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D004195:Disease Models, Animal; D006801:Humans; D058449:Intravitreal Injections; D017075:Laser Coagulation; D037121:Plant Lectins / Q000737:chemistry; D011897:Random Allocation; D051381:Rats; D013194:Staining and Labeling / Q000379:methods; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C045475:Griffonia simplicifolia lectins; D037121:Plant Lectins; D040301:Vascular Endothelial Growth Factor Receptor-2; C570591:olinvacimab